Instruction 1(b).

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

/ashington,	D.C.	20549
vasimigton,	D.O.	20070

STATEMENT	OF (CHANGES	IN B	ENEFICIAL	OWNERSHIP
O 17 11 = 111 = 11 1	U . •	J, O_O			O 1111121101111

OMB APPROVAL										
OMB Number: 3235-028										
Estimated average burden										
hours per response:										

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* BENEVICH ERIC					N	2. Issuer Name and Ticker or Trading Symbol NEUROCRINE BIOSCIENCES INC NBIX										ionship of Reportir all applicable) Director Officer (give title		10% O		wner
(Last) (First) (Middle) 12780 EL CAMINO REAL						3. Date of Earliest Transaction (Month/Day/Year) 02/06/2024										below) below) Chief Commercial Officer				
						4. If Amendment, Date of Original Filed (Month/Day/Year)									6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City)	(St		Zip)		X	Chec satisf	this by the a	box to i	indica	ate that a	a trar	itions of Rule	s made e 10b5-1	pursuant to a	truction	า 10.	ruction or writ	ten pl	an that is inte	ended to
1 Title of 9	Socurity (Inc		I -	Non-Deriva		Secu 2A. Dee			cqu	ıired,	_	-	-		ially		ed ount of	6.0	wnership	7. Nature
			Date (Month/Day/Ye	Execution		on Dat	te,	Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 an				d 5) Se Be Ov Fo		Securities Beneficially Dwned Following		m: Direct or rect (I)	of Indirect Beneficial Ownership (Instr. 4)	
									Code	ode V		nount	(A) or (D)) or Price		Reported Transaction(s) (Instr. 3 and 4)				
Common Stock 02			02/06/202	4				S ⁽¹⁾		1,280		D	\$142.11	172(2)		38,751		D		
Common Stock 02/08/2024				1			S ⁽³⁾			980 D \$134.		\$134.19	25 ⁽⁴⁾	25 ⁽⁴⁾ 39,631		D				
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	Exe if a	Deemed ecution Date, any onth/Day/Year)		saction e (Instr.	of Der Sec (A) Dis of (rivativ curitie quired or sposec	re (I es d	Expiration Date e (Month/Day/Year) S L L S				Amount of Securities		rice of ivative urity tr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s (Instr. 4)	,	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)
					Code	e V	(A)) (D)		Date Exercisa	ıble	Expiration Date	n Title	Amount or Number of Shares	1					

Explanation of Responses:

- 1. Sale of 1,280 shares of common stock issued upon vesting of 2,430 restricted stock units on February 6, 2024 to cover payroll and withholding taxes, with the balance of the shares (1,150) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2021. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
- 2. Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from \$141.04 to \$142.96. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- 3. Sale of 980 shares of common stock issued upon vesting of 1,860 restricted stock units on February 8, 2024 to cover payroll and withholding taxes, with the balance of the shares (880) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2021. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
- 4. Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from \$132.64 to \$136.36. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Remarks:

/s/ Darin Lippoldt, Attorney-

02/08/2024

in-Fact

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.